drugset / Trial / NCT07249554

Combination Therapy for Alcohol Use Disorder

NCT07249554

Phase 2 Not yet recruiting 45 enrolled Johns Hopkins University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This human laboratory study will collect preliminary safety and efficacy data from a sample of participants enrolled in a 4-week in-patient treatment program for alcohol use disorder.

Timeline

Start
2026-09
Primary completion
2028-07
Completion
2028-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Naltrexone Small molecule Oral
Subject Semaglutide Peptide 7 mg Oral